Amicus Therapeutics Inc (NASDAQ: FOLD) is -20.79% lower on its value in year-to-date trading and has touched a low of $9.02 and a high of $14.57 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FOLD stock was last observed hovering at around $11.74 in the last trading session, with the day’s loss setting it -0.5%.
Currently trading at $11.24, the stock is -0.61% and 0.88% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.34 million and changing -4.26% at the moment leaves the stock 1.02% off its SMA200. FOLD registered -0.62% loss for a year compared to 6-month loss of 10.85%. The firm has a 50-day simple moving average (SMA 50) of $11.1462 and a 200-day simple moving average (SMA200) of $11.13295.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.95% gain in the last 1 month and extending the period to 3 months gives it a -0.71%, and is -2.94% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.71% over the week and 4.10% over the month.
Amicus Therapeutics Inc (FOLD) has around 517 employees, a market worth around $3.33B and $493.67M in sales. Fwd P/E is 84.91. Profit margin for the company is -21.21%. Distance from 52-week low is 24.61% and -22.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.02%).
Amicus Therapeutics Inc quarterly earnings per share for the current quarter are estimated at 0.0 with sales reaching $135.33M over the same period.The EPS is expected to grow by 63.18% this year, but quarterly earnings will post 29.50% year-over-year. Quarterly sales are estimated to grow 30.80% in year-over-year returns.
352.0 institutions hold shares in Amicus Therapeutics Inc (FOLD), with institutional investors hold 107.41% of the company’s shares. The shares outstanding are 293.59M, and float is at 289.03M with Short Float at 7.59%. Institutions hold 106.61% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 28.59 million shares valued at $283.6 million. The investor’s holdings represent 9.4382 of the FOLD Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 28.06 million shares valued at $278.33 million to account for 9.2629 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 27.4 million shares representing 9.0458 and valued at over $271.81 million, while BLACKROCK INC. holds 8.046 of the shares totaling 24.37 million with a market value of $241.77 million.
Amicus Therapeutics Inc (FOLD) Insider Activity
Amicus Therapeutics Inc disclosed in a document filed with the SEC on Nov 01 ’24 that Campbell Bradley L (President and CEO) sold a total of 7,500 shares of the company’s common stock. The trade occurred on Nov 01 ’24 and was made at $11.46 per share for $85960.0. Following the transaction, the insider now directly holds 0.89 million shares of the FOLD stock.
Still, SEC filings show that on Nov 01 ’24, BRADLEY CAMPBELL (Director) Proposed Sale 7,500 shares at an average price of $11.42 for $85650.0. The insider now directly holds shares of Amicus Therapeutics Inc (FOLD).
